Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant DES Strategy Will Be Guided By Bare-Metal Stent Experience

This article was originally published in The Gray Sheet

Executive Summary

Guidant will support its initial drug-eluting stent PMA submission with the 975-patient FUTURE IV randomized, pivotal trial, slated to begin at up to 70 sites in the second quarter of 2004

You may also be interested in...



Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes

Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing

Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes

Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing

Cypher Revenue Stream Counters Some DES Damage To Guidant Stent Sales

Guidant's co-promotion and catheter supply agreements with Cordis generated revenue of $21 mil. in Q1, slightly assuaging the impact of drug-eluting stents on bare-metal sales

Related Content

UsernamePublicRestriction

Register

MT019365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel